Loading organizations...
CARGO Therapeutics has raised $200.0M across 1 funding round.
Key people at CARGO Therapeutics.
CARGO Therapeutics has raised $200.0M in total across 1 funding round.
CARGO Therapeutics is a clinical-stage biotechnology company based in San Mateo, California, that develops next-generation CAR T-cell therapies for cancer patients with relapsed or resistant lymphoma. The organization utilizes proprietary cell engineering platforms to overcome treatment resistance, advancing its lead autologous CD22-targeting candidate, CRG-022, into Phase 2 clinical trials for patients with unmet medical needs. In March 2023, the enterprise secured $200 million in an oversubscribed Series A financing round to fund its clinical pipeline and operations. This funding was co-led by prominent healthcare investors including Third Rock Ventures, RTW Investments, and Perceptive Xontogeny. Following this capital injection, the company scaled its workforce from approximately 50 employees to a projected headcount of over 100 personnel. CARGO Therapeutics was originally founded in 2019 as Syncopation Life Sciences by Crystal Mackall, Robbie Majzner, and Nancy Goodman.
CARGO Therapeutics has raised $200.0M in total across 1 funding round.
CARGO Therapeutics's investors include Third Rock Ventures, Perceptive Xontogeny Venture Fund, RTW Investments, Ally Bridge Group, Cormorant Asset Management, Emerson Collective, Janus Henderson Investors, Nextech, Piper Heartland Healthcare Capital, Red Tree Venture Capital, Samsara BioCapital, T. Rowe Price Associates.
Key people at CARGO Therapeutics.
CARGO Therapeutics has raised $200.0M across 1 funding round. Most recently, it raised $200.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $200M Series A | Third Rock Ventures, Perceptive Xontogeny Venture Fund, RTW Investments | Ally Bridge Group, Cormorant Asset Management, Emerson Collective, Janus Henderson Investors, Nextech, Piper Heartland Healthcare Capital, RED Tree Venture Capital, Samsara BioCapital, T. Rowe Price Associates, Wellington Management | Announced |
CARGO Therapeutics is a clinical-stage biotechnology company developing engineered cell therapies, specifically CAR T-cell therapies, aimed at providing potentially curative treatments for cancer patients.[1][2] It focuses on products like CRG-023, a tri-specific CAR T candidate in Phase 1 trials targeting three B-cell malignancies, and an allogeneic platform to reduce immune rejection for durable responses.[1] The company serves oncology patients, addressing unmet needs in cancer treatment by engineering more effective, off-the-shelf therapies; it went public in November 2023 with 167 employees and demonstrates growth through $591M in total funding.[1][2]
CARGO Therapeutics was incorporated in 2019 as Syncopation Life Sciences, Inc., rebranding to its current name in September 2022.[1] Some sources list a founding year of 2021, with headquarters in San Carlos or San Mateo, California.[1][2][3] Led by CEO Anup Radhakrishnan, the company emerged from efforts to advance CAR T-cell technologies, achieving early traction via multiple funding rounds totaling $591M, including a $110M recent raise, before its NASDAQ IPO (ticker: CRGX) on November 10, 2023, at $15 per share.[1][2] This pivot and public listing marked pivotal moments in scaling its clinical pipeline.
CARGO Therapeutics rides the wave of CAR T-cell therapy expansion, a key trend in immuno-oncology where engineered T-cells target cancers more precisely than traditional treatments.[1][2] Timing aligns with maturing allogeneic platforms, reducing manufacturing costs and patient wait times amid rising demand for scalable cancer cures—global CAR T markets are projected to grow as approvals increase for solid tumors and autoimmune uses. Market forces like FDA fast-tracking and investor interest in biotech IPOs (post-2023 listing) favor it, while its innovations influence the ecosystem by pushing tri-specific and rejection-resistant designs, potentially lowering barriers for broader adoption in healthcare.[1]
CARGO's Phase 1 data readouts for CRG-023 and allogeneic advancements will drive milestones, with trends like AI-optimized cell engineering and combo therapies shaping its path toward Phase 2/3 trials and partnerships.[1] Influence may evolve through expanded indications beyond B-cell malignancies, amplifying its role in accessible, curative oncology if rejection hurdles are cleared. This positions CARGO as a momentum player in biotech's cell therapy frontier, building on its public foundation for sustained impact.
